Progressive discontinuation of antihypertensive medications did not lower risk for mortality compared with usual care among ...

Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive ...

The European Medicines Agency has confirmed suspension of marketing authorization for Pfizer's now-withdrawn Oxbryta for ...

Pembrolizumab (Keytruda) administered before and after surgery reduced the risk of death by 26% vs placebo in patients with early-stage non–small cell lung cancer (NSCLC), according to 5-year ...

Event-free survival (EFS) improved by 60% and overall survival (OS) by 50% with the antibody-drug conjugate (ADC) enfortumab vedotin (Padcev) plus pembrolizumab (Keytruda) versus upfront radical ...

Atezolizumab improved DFS and OS in ctDNA-positive MIBC patients, with a median DFS of 9.9 months vs 4.8 months for placebo. Serial ctDNA testing may offer a more accurate assessment of MRD and early ...

Physicians and patient advocacy groups are rallying behind a renewed legislative effort in Congress to amend what they claim ...

Moment of Clarity has released a new resource, titled “Using TMS Therapy for BPD Recovery,” now available on their website.

In the intent-to-treat population, the median progression-free survival (PFS) was 8.77 months with giredestrant plus Afinitor ...

Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate ...

But these days, everyday folks, influencers and medical experts alike are talking about the many frustrating symptoms ...